A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Therapeutic Use
- Acronyms COMMIT
- Sponsors Flex Pharma
- 11 Oct 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.
- 31 Jul 2017 According to a Flex Pharma media release, company is on track to initiate the trial this quarter and data readouts expected in 2018.
- 25 Jul 2017 According to a Flex Pharma media release, the trial is expected to initiate in third quarter 2017.